These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12462153)

  • 1. Non-fluorinated quinolones (NFQs): new antibacterials with unique properties against quinolone-resistant gram-positive pathogens.
    Roychoudhury S; Ledoussal B
    Curr Drug Targets Infect Disord; 2002 Mar; 2(1):51-65. PubMed ID: 12462153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
    Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
    J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The possibility of drug design of quinolones effective for multiresistant gram-positive pathogens].
    Hayakawa I
    Nihon Rinsho; 1997 May; 55(5):1266-71. PubMed ID: 9155185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of temafloxacin hydrochloride (TA-167 or A-62254), a new fluorinated 4-quinolone.
    Nakanishi N; Inoue M; Inoue K; Yamaguchi T; Mitsuhashi S
    Chemotherapy; 1990; 36(5):345-55. PubMed ID: 2209168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro and in vivo antibacterial activities of pazufloxacin mesilate, a new injectable quinolone].
    Nomura N; Mitsuyama J; Furuta Y; Yamada H; Nakata M; Fukuda T; Yamada H; Takahata M; Minami S
    Jpn J Antibiot; 2002 Aug; 55(4):412-39. PubMed ID: 12378871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations.
    Roychoudhury S; Twinem TL; Makin KM; Nienaber MA; Li C; Morris TW; Ledoussal B; Catrenich CE
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3422-6. PubMed ID: 11709318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone.
    Yamakawa T; Mitsuyama J; Hayashi K
    J Antimicrob Chemother; 2002 Mar; 49(3):455-65. PubMed ID: 11864945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
    Anderson VE; Osheroff N
    Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
    Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
    Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preparation and in vitro and in vivo evaluation of quinolones with selective activity against gram-positive organisms.
    Cooper CS; Klock PL; Chu DT; Hardy DJ; Swanson RN; Plattner JJ
    J Med Chem; 1992 Apr; 35(8):1392-8. PubMed ID: 1573632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria.
    Emami S; Shafiee A; Foroumadi A
    Mini Rev Med Chem; 2006 Apr; 6(4):375-86. PubMed ID: 16613574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance.
    Pan XS; Fisher LM
    J Bacteriol; 1996 Jul; 178(14):4060-9. PubMed ID: 8763932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J; Thanassi JA; Thoma CL; Bradbury BJ; Deshpande M; Pucci MJ
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fluoroquinolone antibacterials: past, present and future perspectives.
    Appelbaum PC; Hunter PA
    Int J Antimicrob Agents; 2000 Sep; 16(1):5-15. PubMed ID: 11185413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of lomefloxacin (SC-47111) and other quinolones.
    Sun ZM; Maskell JP; Sehgal SC; Williams JD
    Infection; 1989; 17(3):165-7. PubMed ID: 2737760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.